- Conditions
- Hypertension, Pulmonary, Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine, Standardized meals
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 81
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Congenital Heart Disease
- Interventions
- Remodulin
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Columbus, Ohio
- Conditions
- Pulmonary Hypertension
- Interventions
- treprostinil sodium
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Congenital Heart Disease
- Interventions
- Treprostinil, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
- Conditions
- Healthy Volunteers
- Interventions
- C16TR, Placebo, Tyvaso®
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- Prospective study assessments
- Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Remunity Pump for Remodulin
- Combination Product
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Raynaud's Disease, Raynaud Phenomena, Raynauds
- Interventions
- Oral treprostinil (UT-15C) sustained release tablets
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Sclerosis
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • San Francisco, California • Torrance, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Fresno, California • Torrance, California • Orlando, Florida + 8 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- treprostinil, Crono Five ambulatory pump
- Drug · Device
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- San Francisco, California • New York, New York • Oklahoma City, Oklahoma
- Conditions
- Hypertension, Pulmonary
- Interventions
- treprostinil inhalations, tadalafil
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Stanford, California • Chicago, Illinois
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 51
- States / cities
- La Jolla, California • Los Angeles, California • Pasadena, California + 45 more
- Conditions
- Peripheral Vascular Disease
- Interventions
- Remodulin (treprostinil sodium) Injection
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 4
- States / cities
- Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Persistent Pulmonary Hypertension of the Newborn
- Interventions
- IV Remodulin, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 1 Hour to 14 Days
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more
- Conditions
- PAH
- Interventions
- oral treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 9
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Liver Transplant
- Interventions
- treprostinil sodium, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- treprostinil diethanolamine, placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Treprostinil sodium for inhalation
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more